The treatment for COVID-19 has evolved rapidly since the start of the pandemic and now
consists mainly of antiviral and immunomodulatory agents. Antivirals, such as remdesivir …

Data regarding the occurrence of venous thromboembolic events (VTE), including acute
pulmonary embolism (PE) and deep vein thrombosis (DVT) in recovered COVID-19 patients …

В конце 2019 г. в Китайской Народной Республике (КНР) произошла вспышка новой
коронавирусной инфекции с эпицентром в городе Ухань (провинция Хубэй). Всемирная …

COVID-19 is associated with endothelial activation in the setting of a potent inflammatory
reaction and a hypercoagulable state. The end result of this thromboinflammatory state is an …

Three years after the start of the pandemic, approaches to the prevention and treatment of
acute Covid-19 have been established. However, post-acute sequelae of SARS-CoV-2 …

Background: COVID-19 (coronavirus disease 2019) is associated with heightened risks of
venous and arterial thrombosis and hospitalization due to respiratory failure. To assess …

This COVID‐19 outpatient randomized controlled trials (RCTs) systematic review compares
hospitalization outcomes amongst four treatment classes over pandemic period, geography …

Abstract Coronavirus disease 2019 (COVID-19) associated coagulopathy is multifactorial
and involves inflammation driven hypercoagulability, endothelial dysfunction, platelet …

Coronavirus disease 2019 (COVID-19) has been shown to be strongly associated with
increased risk for venous thromboembolism events (VTE) mainly in the inpatient but also in …

Introduction The benefits of early thromboprophylaxis in symptomatic COVID-19 outpatients
remain unclear. We present the 90-day results from the randomised, open-label, parallel …